Welcome to our dedicated page for Portage Biotech news (Ticker: PRTG), a resource for investors and traders seeking the latest updates and insights on Portage Biotech stock.
Portage Biotech Inc (PRTG) is a clinical-stage biopharmaceutical company advancing novel immuno-oncology therapies through strategic research and development. This news hub provides investors and industry observers with timely updates on clinical milestones, partnership announcements, and corporate developments essential for understanding the company's progress in addressing unmet medical needs.
Our curated collection offers comprehensive access to official press releases and verified news coverage related to PRTG's therapeutic pipeline, including combination therapies targeting immune resistance. Users will find updates on clinical proof-of-concept studies, regulatory developments, and strategic collaborations that shape the company's position in the biotech sector.
The resource prioritizes updates across three key areas: clinical trial advancements, research partnerships, and financial disclosures. Each category maintains focus on material developments while avoiding speculative commentary, ensuring users receive actionable information aligned with investment research requirements.
Bookmark this page for streamlined access to Portage Biotech's latest developments in immuno-oncology innovation. Regularly updated content serves as a reliable foundation for monitoring the company's progress through critical clinical and corporate milestones.
Portage Biotech Inc. (NASDAQ: PRTG) has announced the acceptance of a poster presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023, in Chicago, IL. The poster will present updated data from the Phase 1/2 trial of its lead invariant natural killer T cell (iNKT) engager program, PORT-2 (IMM60), which is being evaluated alone and in combination with pembrolizumab for patients with advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
The presentation is entitled 'IMPORT-201 (IMP-MEL): A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of a Novel iNKT Agonist IMM60 and Pembrolizumab.' It is set for June 3, 2023, from 8:00-11:00 a.m. CDT with abstract number 2575. Portage aims to leverage innovative trial designs to identify patient populations most likely to benefit from their therapies.
Biohaven Ltd. (NYSE: BHVN) has made significant strides in its clinical development, launching a pivotal Phase 3 study for its myostatin-targeting agent for spinal muscular atrophy. The company initiated a Phase 1 clinical trial for a new TYK2/JAK1 inhibitor, BHV-8000, and reported promising Phase 1 safety data for BHV-7000, which targets epilepsy and mood disorders. The 2022 financial results showed a net loss of $570.3 million, driven by increased R&D expenses. With $465 million in cash, Biohaven is well-positioned for future growth, anticipating major milestones in 2023, including multiple IND submissions and further advancements in their extensive neuroscience pipeline.
FAQ
What is the current stock price of Portage Biotech (PRTG)?
What is the market cap of Portage Biotech (PRTG)?
